SCM
CEROW

Shaolin Capital Management’s CERo Therapeutics Warrants CEROW Stock Holding History

Shaolin Capital Management’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-374,998
Closed -$23K – 625
2023
Q2 		$23K Buy
+374,998
New +$16.3K ﹤0.01% 461

Other funds holding CEROW

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 50.48% 1-Year Est. Return

Shaolin Capital Management's CEROW Position: Q3 2024 in Review

Shaolin Capital Management sold out of CERo Therapeutics Warrants (CEROW) in Q3 2024, closing a stake of 267,599 shares — an estimated $5.38K sold.

Shaolin Capital Management first reported a position in CEROW in Q4 2022 and held it in 6 quarters. The position peaked at $27K in Q3 2023. 30 funds tracked by Wall St. Rank hold CEROW as of Q3 2024.

  • Shaolin Capital Management reported no remaining CERo Therapeutics Warrants position as of Q3 2024 after selling out during the quarter.
  • Shaolin Capital Management sold 267,599 CERo Therapeutics Warrants shares in Q3 2024, an estimated $5.38K.
  • Shaolin Capital Management first reported a position in CERo Therapeutics Warrants in Q4 2022 and held it in 6 quarters.
  • Shaolin Capital Management's CERo Therapeutics Warrants position peaked at $27K in Q3 2023.
  • 30 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q3 2024.

Based on Shaolin Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.